熱門資訊> 正文
中国SXT制药将合并1比150
2026-01-30 22:36
- China SXT Pharmaceutics (Nasdaq: SXTC) Friday said that it will implement a 1-for-150 share consolidation effective February 3, 2026.
- The company’s Class A ordinary shares are expected to begin trading on a post-consolidation basis on Nasdaq on that date under the symbol “SXTC,” with a new CUSIP number.
- Fractional shares will be rounded up to the next whole share.
- China SXT said it had about 143.7 million Class A shares outstanding before the consolidation, which will be reduced to roughly 957,960 shares after the consolidation.
- All outstanding options, warrants, and other rights to purchase Class A shares will be adjusted proportionately.
- SXTC is -21.4% to $0.0393.
- Source: Press Release
More on China SXT Pharmaceuticals
- Seeking Alpha’s Quant Rating on China SXT Pharmaceuticals
- Financial information for China SXT Pharmaceuticals
推薦文章
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
一周IPO | 賺錢效應持續火熱！年內24只上市新股「0」破發；「圖模融合第一股」海致科技首日飆漲逾242%
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
